Table 2.
Distribution of PNL by Baseline Subgroups and Follow-up Time
| Overall PNL | PNL < 10% | PNL 10%-50% | PNL > 50% | |
|---|---|---|---|---|
| Age, y | ||||
| <18 | 0.24 [0.05-0.56] | 54 (31.8%) | 67 (39.4%) | 49 (28.8%) |
| ≥18 | 0.01 [0.00-0.12] | 199 (70.3%) | 62 (21.9%) | 22 (7.8%) |
| Sex | ||||
| Female | 0.05 [0.00-0.27] | 105 (57.4%) | 55 (30.1%) | 23 (12.6%) |
| Male | 0.05 [0.00-0.30] | 148 (54.8%) | 74 (27.4%) | 48 (17.8%) |
| Race | ||||
| White | 0.03 [0.00-0.21] | 155 (61.3%) | 67 (26.5%) | 31 (12.3%) |
| Black | 0.09 [0.00-0.35] | 62 (53.4%) | 35 (30.2%) | 19 (16.4%) |
| Other | 0.12 [0.00-0.49] | 36 (45.0%) | 25 (31.3%) | 19 (23.8%) |
| Ethnicity | ||||
| Hispanic | 0.11 [0.01-0.43] | 42 (46.7%) | 30 (33.3%) | 18 (20.0%) |
| Non-Hispanic | 0.04 [0.00-0.27] | 210 (58.5%) | 98 (27.3%) | 51 (14.2%) |
| Diagnosis | ||||
| FSGS | 0.03 [0.00-0.14] | 50 (62.5%) | 23 (28.8%) | 7 (8.8%) |
| MCD | 0.17 [0.04-0.47] | 52 (37.4%) | 54 (38.8%) | 33 (23.7%) |
| MN | 0.01 [0.00-0.26] | 52 (60.5%) | 24 (27.9%) | 10 (11.6%) |
| Other | 0.01 [0.00-0.18] | 99 (66.9%) | 28 (18.9%) | 21 (14.2%) |
| Baseline eGFR, mL/min/1.73 m2 | ||||
| ≤60 | 0.00 [0.00-0.10] | 96 (75.0%) | 24 (18.8%) | 8 (6.3%) |
| 60-120 | 0.07 [0.01-0.30] | 145 (53.9%) | 78 (29.0%) | 46 (17.1%) |
| >120 | 0.37 [0.13-0.56] | 12 (21.4%) | 27 (48.2%) | 17 (30.4%) |
| Baseline UPCR, mg/mg | ||||
| 0-0.3 | 0.08 [0.01-0.23] | 41 (56.2%) | 18 (24.7%) | 14 (19.2%) |
| 0.3-1.0 | 0.05 [0.00-0.26] | 44 (61.1%) | 18 (25.0%) | 10 (13.9%) |
| 1.0-3.0 | 0.01 [0.00-0.14] | 83 (68.6%) | 30 (24.8%) | 8 (6.6%) |
| >3.0 | 0.11 [0.01-0.39] | 84 (48.0%) | 56 (32.0%) | 35 (20.0%) |
| Baseline medication use | ||||
| Steroids | 0.17 [0.03-0.49] | 64 (39.8%) | 57 (35.4%) | 40 (24.8%) |
| RAASi | 0.02 [0.00-0.19] | 130 (61.3%) | 60 (28.3%) | 22 (10.4%) |
| CNI | 0.27 [0.05-0.60] | 12 (29.3%) | 12 (29.3%) | 17 (41.5%) |
| Diuretics | 0.03 [0.00-0.24] | 88 (58.3%) | 42 (27.8%) | 21 (13.9%) |
| Follow-up duration | ||||
| 1 y | 0.28 [0.09-0.58] | 24 (25.0%) | 42 (43.8%) | 30 (31.3%) |
| 2 y | 0.11 [0.01-0.45] | 45 (46.4%) | 32 (33.0%) | 20 (20.6%) |
| 3 y | 0.04 [0.00-0.16] | 47 (62.7%) | 20 (26.7%) | 8 (10.7%) |
| 4 y | 0.01 [0.00-0.12] | 123 (72.4%) | 35 (20.6%) | 12 (7.1%) |
| 5 y | 0.00 [0.00-0.04] | 14 (93.3%) | 0 (0%) | 1 (6.7%) |
Note: Values for categorical variables are given as percentages; values for continuous variables are given as median [interquartile range].
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN, membranous nephropathy; PNL, probability of nonlinearity; RAASi, renin-angiotensin-aldosterone system inhibitor; UPCR, urinary protein-creatinine ratio.